Effect of chronic hydroxychloroquine use on COVID-19 risk in patients with rheumatoid arthritis and systemic lupus erythematosus: a multicenter retrospective cohort.
J Int Med Res
; 50(4): 3000605221090363, 2022 Apr.
Article
in English
| MEDLINE | ID: covidwho-1779533
ABSTRACT
OBJECTIVE:
Hydroxychloroquine (HCQ) has been used during the coronavirus disease 2019 (COVID-19) pandemic because of its reported anti-viral activity. This study examined the association of chronic HCQ use with the incidence and complications of COVID-19.METHODS:
This retrospective cohort study included adults with rheumatoid arthritis and/or systemic lupus erythematosus who visited rheumatology clinics in three tertiary hospitals in Riyadh, Saudi Arabia between January 2019 and December 2020. Patients were categorized into two groups based on HCQ use. Data were obtained from the electronic health record and by interviews with patients. The primary study objective was the incidence of COVID-19 and its complications from March 2020 to February 2021.RESULTS:
Almost 11% of the study cohort was positive for COVID-19, and the incidence of COVID-19 was similar between HCQ users (11.11%) and nonusers (10.86%). Disease complication rates were similar in the study arms, and they mainly included fever, dry cough, fatigue, and breathing difficulty.CONCLUSIONS:
This study revealed no significant association between chronic HCQ use and the incidence of COVID-19, and disease complications were similar in the study arms.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Arthritis, Rheumatoid
/
Antirheumatic Agents
/
COVID-19
/
COVID-19 Drug Treatment
/
Lupus Erythematosus, Systemic
Type of study:
Cohort study
/
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Topics:
Long Covid
Limits:
Adult
/
Humans
Language:
English
Journal:
J Int Med Res
Year:
2022
Document Type:
Article
Affiliation country:
03000605221090363
Similar
MEDLINE
...
LILACS
LIS